Zobrazeno 1 - 10
of 101
pro vyhledávání: '"Hidekatsu, Kuroda"'
Autor:
Takashi Kumada, Hidenori Toyoda, Sadanobu Ogawa, Tatsuya Gotoh, Yasuaki Suzuki, Kento Imajo, Katsutoshi Sugimoto, Tatsuya Kakegawa, Hidekatsu Kuroda, Yutaka Yasui, Nobuharu Tamaki, Masayuki Kurosaki, Namiki Izumi, Tomoyuki Akita, Junko Tanaka, Atsushi Nakajima
Publikováno v:
Ultrasonography, Vol 43, Iss 2, Pp 121-131 (2024)
Purpose The effect of hepatic fibrosis stage on quantitative ultrasound based on the attenuation coefficient (AC) for liver lipid quantification is controversial. The objective of this study was to determine how the degree of fibrosis assessed by mag
Externí odkaz:
https://doaj.org/article/647743be5df641a4b63be42d5a65b18c
Autor:
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Keisuke Yokohama, Hiroki Nishikawa, Takashi Nishimura, Noritomo Shimada, Kazuhito Kawata, Hisashi Kosaka, Atsushi Naganuma, Yutaka Yata, Hideko Ohama, Hidekatsu Kuroda, Kazunari Tanaka, Takaaki Tanaka, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada, the Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publikováno v:
Cancer Medicine, Vol 12, Iss 24, Pp 21680-21693 (2023)
Abstract Aim This retrospective study compared the impact of atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib (LEN) on the liver function in patients with hepatocellular carcinoma. Methods We included 526 patients who received Atez/Bev and 731
Externí odkaz:
https://doaj.org/article/47d83858206f4fedb8133cae3683b6fd
Autor:
Masashi Ninomiya, Mio Tsuruoka, Jun Inoue, Atsushi Hiraoka, Tomoaki Iwata, Akitoshi Sano, Kosuke Sato, Masazumi Onuki, Satoko Sawahashi, Hidekatsu Kuroda, Takayoshi Oikawa, Masashi Fujita, Kazumichi Abe, Tomohiro Katsumi, Wataru Sato, Go Igarashi, Chikara Iino, Tetsu Endo, Nobukazu Tanabe, Hiroshi Numao, Katsunori Iijima, Takayuki Matsumoto, Hiromasa Ohira, Yoshiyuki Ueno, Atsushi Masamune
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract It is difficult to determine whether an individual therapy contributes to the elongation of survival because of the difficulty of organizing clinical research in patients who receive multiple treatments in HCC. We aimed to establish a new mo
Externí odkaz:
https://doaj.org/article/11d8cecf2b5d4cb8a1e0c970a7172a60
Autor:
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Takeshi Hatanaka, Joji Tani, Koichi Takaguchi, Masanori Atsukawa, Ei Itobayashi, Takashi Nishimura, Kunihiko Tsuji, Kazuto Tajiri, Toru Ishikawa, Satoshi Yasuda, Hidenori Toyoda, Shinya Fukunishi, Chikara Ogawa, Satoru Kakizaki, Noritomo Shimada, Atsushi Naganuma, Kazuhito Kawata, Hisashi Kosaka, Hidekatsu Kuroda, Tomomitsu Matono, Yutaka Yata, Hironori Ochi, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Keisuke Yokohama, Hiroki Nishikawa, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Hiroko Iijima, Masaki Kaibori, Yoichi Hiasa, Takashi Kumada, Representing the Real‐life Practice Experts for HCC Study Group with Hepatocellular Carcinoma experts from 48 clinics in Japan (RELPEC/HCC 48 Group)
Publikováno v:
Cancer Reports, Vol 7, Iss 4, Pp n/a-n/a (2024)
Abstract Aims The aim of the present study was to elucidate detailed parameters for prediction of prognosis for patients with unresectable hepatocellular carcinoma (uHCC) receiving atezolizumab plus bevacizumab (Atez/Bev) treatment. Methods A total o
Externí odkaz:
https://doaj.org/article/db2c34e45940412fa92f5beffa4e949a
Autor:
Kazuhiro Nouso, Shohei Shiota, Rio Fujita, Akiko Wakuta, Kazuya Kariyama, Atsushi Hiraoka, Masanori Atsukawa, Joji Tani, Toshifumi Tada, Shinichiro Nakamura, Kazuto Tajiri, Masaki Kaibori, Masashi Hirooka, Ei Itobayashi, Satoru Kakizaki, Atsushi Naganuma, Toru Ishikawa, Takeshi Hatanaka, Shinya Fukunishi, Kunihiko Tsuji, Kazuhito Kawata, Koichi Takaguchi, Akemi Tsutsui, Chikara Ogawa, Hironori Ochi, Yutaka Yata, Hidekatsu Kuroda, Hiroko Iijima, Tomomitsu Matono, Noritomo Shimada, Satoshi Yasuda, Hidenori Toyoda, Takashi Kumada, the Real‐life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publikováno v:
Cancer Medicine, Vol 12, Iss 17, Pp 17849-17855 (2023)
Abstract Aim Multiple studies have revealed the correlation between gut microbiome and the response to checkpoint inhibitors (CPIs) in patients with cancer, and oral administration of butyrate‐producing enterobacteria has been reported to enhance t
Externí odkaz:
https://doaj.org/article/63364b06136f40709acc82310c3985ee
Autor:
Keisuke Kakisaka, Nobuaki Nakayama, Kotaro Kumagai, Takuro Hisanaga, Takayuki Kondo, Toru Setsu, Shunsuke Sato, Yohei Kooka, Kei Endo, Yuichi Yoshida, Takayoshi Oikawa, Hidekatsu Kuroda, Akio Miyasaka, Ryuzo Abe, Taka-aki Nakada, Yoshihiro Ikura, Kenichi Harada, Takuya Genda, Shuji Terai, Naoya Kato, Taro Takami, Akio Ido, Satoshi Mochida, Takayuki Matsumoto, Atsushi Tanaka
Publikováno v:
Gastro Hep Advances, Vol 2, Iss 4, Pp 497-504 (2023)
Background and Aims: Acute liver injury (ALI) due to autoimmune hepatitis (AIH) can be treated by immunosuppression. In contrast, idiosyncratic drug-induced liver injury (DILI) had a poor prognosis. DILI thus needs to be distinguished from non-DILI.
Externí odkaz:
https://doaj.org/article/41e7930ab9084fc1bab5aaa463fc1040
Autor:
Kei Endo, Keisuke Kakisaka, Hidekatsu Kuroda, Akio Miyasaka, Yasuhiro Takikawa, Takayuki Matsumoto
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Sarcopenia is a common complication in patients with chronic liver disease (CLD); however, the progression of sarcopenia over the course of CLD is unclear. The present study therefore determined the natural course of the progression of sarco
Externí odkaz:
https://doaj.org/article/38c232aea35e49209806209d75147646
Autor:
Masatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, Kaoru Tsuchiya, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Naoshi Nishida, Chikara Ogawa, Tetsu Tomonari, Noriaki Nakamura, Hidekatsu Kuroda, Atsushi Takebe, Yoshifumi Takeyama, Masaaki Hidaka, Susumu Eguchi, Stephen L Chan, Masayuki Kurosaki, Namiki Izumi
Publikováno v:
Liver Cancer (2023)
Introduction: Atezolizumab plus bevacizumab therapy is extremely effective in the treatment of intermediate-stage hepatocellular carcinoma (HCC), with a response rate of 44%, as reported in the IMbrave150 trial. When tumor shrinkage is obtained, achi
Externí odkaz:
https://doaj.org/article/332e0f13cacf47a9aac3a9b2a4a83f4a
Autor:
Masashi Fujita, Kazumichi Abe, Hidekatsu Kuroda, Takayoshi Oikawa, Masashi Ninomiya, Atsushi Masamune, Kazuo Okumoto, Tomohiro Katsumi, Wataru Sato, Katsunori Iijima, Tetsu Endo, Shinsaku Fukuda, Nobukazu Tanabe, Hiroshi Numao, Yasuhiro Takikawa, Yoshiyuki Ueno, Hiromasa Ohira
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract Sarcopenia is associated with poor prognosis of patients with hepatocellular carcinoma (HCC). We investigated the association of skeletal muscle volume (SMV) and its change in HCC patients taking lenvatinib. In 130 HCC patients, psoas mass i
Externí odkaz:
https://doaj.org/article/90a8f11b5c724eb5964b2dfc5f11d103
Autor:
Keisuke Kakisaka, Takuro Sato, Yasunori Wada, Ai Ito, Hisashi Eto, Hiroaki Abe, Jo Kanazawa, Kenji Yusa, Yohei Kooka, Kei Endo, Yuichi Yoshida, Takayoshi Oikawa, Hidekatsu Kuroda, Akio Miyasaka, Manami Akasaka, Takayuki Matsumoto
Publikováno v:
Molecular Genetics and Metabolism Reports, Vol 32, Iss , Pp 100898- (2022)
Externí odkaz:
https://doaj.org/article/653252260b4845e693333d2bb8c67a40